The US National Institute of Allergy and Infectious Diseases (NIAID) and biotechnology company Moderna are in Phase 1 clinical trials of three different mRNA vaccine formulations designed to immunize against HIV. announced that they started with the vaccine administered to the first participant.
Within the scope of the
Phase 1 (HVTN 302) studies, which will be observed for approximately 1 year, approximately 100 HIV-negative adults aged between 18 and 55 years will be divided into groups and a different vaccine will be administered to each group. The clinical trial along with the vaccination is expected to be completed by July 2023. The scientists hope that at least one of the three formulations will demonstrate strong immune responses and Phase 2 trials can begin.
NIAID director Anthony S. Fauci: “Finding an HIV vaccine has proven to be a daunting scientific challenge. With the success of safe and highly effective COVID-19 vaccines, we have an exciting opportunity to find out if mRNA technology can achieve similar results against HIV infection.”
Covid-19 can cause brain damage even in mild survivors
Stephen Hodge, president of Moderna, has in the past been diagnosed with HIV using more traditional vaccine technologies. said it is difficult to promote immunity against the immune system, but is optimistic that mRNA can be an effective strategy
- Homepage
- Popular Science
- Health News
- Moderna begins Phase 1 trials of 3 different mRNA HIV vaccines
57404
